Apnimed has raised $25 million to develop a pharmacological treatment for obstructive sleep apnea (OSA). The series B financing will enable Apnimed to deliver data from phase 2 trials of its oral drug candidate in the second quarter and push on into late-stage development.

Eliem Therapeutics has exited stealth with $80 million and plans to treat chronic pain, depression, epilepsy and anxiety. The Anglo-American startup will use the money to advance a pipeline led by a palmitoylethanolamide (PEA) prodrug for the treatment of chronic pain.

A phase 3 prostate cancer clinical trial of Novaris’ targeted radioligand therapy 177Lu-PSMA-617 has met both its primary endpoints. The result tees Novartis up to seek approval for a drug it picked up in its $2.1 billion acquisition of Endocyte.

Roche has stopped a phase 3 Huntington’s disease clinical trial after an interim review of the data. The preplanned review found no new safety signals associated with Ionis Pharmaceuticals-partnered antisense drug tominersen, suggesting lack of efficacy may have driven the decision to stop the trial.

After she helped Gilead Sciences repurpose its old Ebola drug remdesivir into the first antiviral for COVID-19, AlloVir is hoping Diana Brainard, M.D., can repeat that same magic as its new CEO.

There is no shortage of companies working to deliver the therapeutic benefits of cytokines without their nasty side effects, from Synthekine and Nektar Therapeutics to Synthorx, which Sanofi bought for $2.5 billion in 2019. The latest entrant to the arena is Asher Bio, a biotech engineering immunotherapies, such as cytokines, that only affect specific immune cell targets.

Stroke-spotting software developer Viz.ai has raised $71 million to help expand its artificial intelligence programs into other acute care areas—including cardiovascular, pulmonary and trauma care—amid plans to take its business to new global markets.

Nearly two years after a $74 million raise, EpimAb Therapeutics is adding another $120 million to its coffers to bankroll the development of its bispecific antibodies. The capital will fuel the journey of three programs through the clinic, including a dual checkpoint inhibitor and a T-cell engager that targets CD3 and BCMA.

Pfizer and Eli Lilly’s long journey to a potential FDA approval for tanezumab still looked rocky today after review documents from the regulator cast doubt over its safety.

XyloCor Therapeutics has raised $22.6 million to study a gene therapy designed to deliver VEGF to heart cells. The financing, which swells the series A to $41.9 million, positions XyloCor to study its lead candidate in patients undergoing coronary artery bypass graft surgery (CABG).